Literature DB >> 32213049

Difference in treatment outcomes between clinical trials and "real-life" clinical practice: ustekinumab in ulcerative colitis.

Daniela Pugliese1, Alessandro Armuzzi1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32213049      PMCID： PMC7006003          DOI： 10.1177/2050640619900575

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN： 2050-6406            Impact factor:   4.623


× No keyword cloud information.
  6 in total

1.  Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.

Authors:  Bruce E Sands; William J Sandborn; Remo Panaccione; Christopher D O'Brien; Hongyan Zhang; Jewel Johanns; Omoniyi J Adedokun; Katherine Li; Laurent Peyrin-Biroulet; Gert Van Assche; Silvio Danese; Stephan Targan; Maria T Abreu; Tadakazu Hisamatsu; Philippe Szapary; Colleen Marano
Journal:  N Engl J Med       Date:  2019-09-26       Impact factor: 91.245

2.  Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review.

Authors:  Mathurin Fumery; Siddharth Singh; Parambir S Dulai; Corinne Gower-Rousseau; Laurent Peyrin-Biroulet; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-16       Impact factor: 11.382

3.  Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population.

Authors:  Christina Ha; Thomas A Ullman; Corey A Siegel; Asher Kornbluth
Journal:  Clin Gastroenterol Hepatol       Date:  2012-02-15       Impact factor: 11.382

4.  One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.

Authors:  A Amiot; M Serrero; L Peyrin-Biroulet; J Filippi; B Pariente; X Roblin; A Buisson; C Stefanescu; C Trang-Poisson; R Altwegg; P Marteau; T Vaysse; A Bourrier; S Nancey; D Laharie; M Allez; G Savoye; J Moreau; L Vuitton; S Viennot; A Aubourg; A-L Pelletier; G Bouguen; V Abitbol; C Gagniere; Y Bouhnik
Journal:  Aliment Pharmacol Ther       Date:  2017-06-08       Impact factor: 8.171

5.  Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission.

Authors:  Alessandro Armuzzi; Daniela Pugliese; Silvio Danese; Gianluca Rizzo; Carla Felice; Manuela Marzo; Gialuca Andrisani; Gionata Fiorino; Orsola Sociale; Alfredo Papa; Italo De Vitis; Gian Lodovico Rapaccini; Luisa Guidi
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

6.  The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis.

Authors:  Bruce E Sands; Adam S Cheifetz; Chudy I Nduaka; Daniel Quirk; Wenjin Wang; Eric Maller; Gary S Friedman; Chinyu Su; Peter D R Higgins
Journal:  J Crohns Colitis       Date:  2019-09-19       Impact factor: 9.071
  6 in total
  2 in total

Review 1.  Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab.

Authors:  Daniela Pugliese; Giuseppe Privitera; Marcello Fiorani; Laura Parisio; Valentin Calvez; Alfredo Papa; Antonio Gasbarrini; Alessandro Armuzzi
Journal:  Therap Adv Gastroenterol       Date:  2022-06-13       Impact factor: 4.802

2.  Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis.

Authors:  Laura A Lucaciu; Nathan Constantine-Cooke; Nikolas Plevris; Spyros Siakavellas; Lauranne A A P Derikx; Gareth-Rhys Jones; Charles W Lees
Journal:  Therap Adv Gastroenterol       Date:  2021-12-23       Impact factor: 4.409
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.